RECURRENT ENDOMETRIAL CANCER
Clinical trials for RECURRENT ENDOMETRIAL CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ENDOMETRIAL CANCER trials appear
Sign up with your email to follow new studies for RECURRENT ENDOMETRIAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for endometrial cancer: targeted drug BNT323 faces chemo in phase 3 trial
Disease control Recruiting nowThis Phase 3 trial tests whether the drug BNT323 (trastuzumab pamirtecan) works better than standard chemotherapy for people with recurrent endometrial cancer that expresses HER2. About 480 participants will be split into two groups based on their HER2 levels. The study measures …
Matched conditions: RECURRENT ENDOMETRIAL CANCER
Phase: PHASE3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for tough endometrial cancer: Four-Drug combo trial launches
Disease control Recruiting nowThis Phase III trial tests whether adding the drug bevacizumab to a standard chemotherapy plus immunotherapy regimen can help people with a specific type of advanced or recurrent endometrial cancer (pMMR, TP53 mutated). About 255 participants will be randomly assigned to one of t…
Matched conditions: RECURRENT ENDOMETRIAL CANCER
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New combo shows promise for Tough-to-Treat uterine cancer
Disease control Recruiting nowThis study tests two drugs, pembrolizumab and lenvatinib, in people with a type of uterine cancer that has come back after initial treatment. The cancer must be mismatch repair proficient, meaning it has a specific genetic feature. The goal is to see if this drug combination can …
Matched conditions: RECURRENT ENDOMETRIAL CANCER
Phase: PHASE2 • Sponsor: University of Miami • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New antibody combo aims to fight back against recurrent ovarian cancer
Disease control Recruiting nowThis study is testing a new drug called ubamatamab, given alone or with another drug called cemiplimab, in people with ovarian cancer or other cancers that have come back after treatment. The main goals are to check safety, find the right dose, and see if the drugs can shrink tum…
Matched conditions: RECURRENT ENDOMETRIAL CANCER
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug combo aims to stall endometrial cancer in High-Risk patients
Disease control Recruiting nowThis study tests whether two drugs, abemaciclib and letrozole, can help keep advanced or recurrent endometrial cancer from getting worse. About 32 people with a specific type of estrogen-sensitive cancer will take these pills daily after initial treatment. The goal is to see if t…
Matched conditions: RECURRENT ENDOMETRIAL CANCER
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC